Phuturdex › Diseases › Mouth Neoplasms
Drugs in development · updated 30 October 2026
Mouth Neoplasms: drugs in development
As of 30 October 2026 there are 48 active clinical trials (recruiting or ongoing, phases I–III) on 49 drugs for mouth Neoplasms. 17 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| APG-157 | III | 2 | NCT07667296 |
| SintilimabSinitilimab, Sindilimab | III | 1 | NCT07827872 |
| Ipatasertib | II | 2 | NCT05172258 |
| CadonilimabAK104, Candonilimab | II | 1 | NCT06728631 |
| CamrelizumabCarrelizumab, Carilizumab | II | 1 | NCT07400094 |
| Ficerafusp alfaBCA101 | I–II | 1 | NCT07552558 |
| INBRX-106 | I–II | 1 | NCT04198766 |
| RRx-001 | II | 1 | NCT05966194 |
| Tirelizumab | II | 1 | NCT05941338 |
| CamonsertibRP-3500 | I | 1 | NCT07156227 |
| Elimusertib | I | 1 | NCT04576091 |
| NBTXR3 | I | 1 | NCT03589339 |
| Nivo800 | I | 1 | NCT07460765 |
| Peposertib | I | 1 | NCT04533750 |
| [64Cu]CM500 | Early I | 1 | NCT07781852 |
| [68Ga]CM500 | Early I | 1 | NCT07781852 |
| Proflavine Hemisulfate | Early I | 1 | NCT02790853 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CisplatinCis Platinum, Cisplatine | II–III | 13 | NCT05063552 |
| PembrolizumabKEYTRUDA, MK-3475 | III | 12 | NCT06589804 |
| CarboplatinCarboplatine, Paraplatin | II–III | 10 | NCT05063552 |
| PaclitaxelTaxol, Paxlitaxel | III | 6 | NCT05721755 |
| CetuximabErbitux | II–III | 4 | NCT05063552 |
| Nab-paclitaxelAbraxane, Nab-placlitaxel | III | 2 | NCT07827872 |
| AtezolizumabTecentriq, MPDL3280A | II–III | 1 | NCT05063552 |
| Bevacizumabavastin, MVASI | II–III | 1 | NCT05063552 |
| DocetaxelTaxotere, Beizray® | II–III | 1 | NCT05063552 |
| Fluorouracil5-Fluorouracil, Adrucil | III | 1 | NCT05721755 |
| CemiplimabREGN2810, Libtayo® | II | 4 | NCT06980038 |
| NivolumabOpdivo, ONO-4538 | II | 4 | NCT05136196 |
| ToripalimabJS001, Teripalimab | II | 2 | NCT07209189 |
| All-trans retinoic acidATRA, Tretinoin | II | 1 | NCT06728631 |
| Aminolevulinic Acid5-Aminolevulinic acid Hydrochloride, Gliolan | II | 1 | NCT06876038 |
Sorted by most advanced phase and number of active trials. Showing 15 of 32 drugs.
All 49 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Salivary gland neoplasm 47 drugs
- Adenoid cystic carcinoma 26 drugs
- Head and neck neoplasms 184 drugs
- Pancreatic neoplasm 395 drugs
- Colorectal neoplasm 534 drugs
- Ovarian neoplasm 411 drugs
- Breast neoplasm 593 drugs
- Head and neck squamous cell carcinoma 321 drugs
- Non-small-cell lung carcinoma 726 drugs
- Metastasis 493 drugs
- Endometrial neoplasm 298 drugs
- Sarcoma 204 drugs
Broader categories
- Stomatognathic disease 4 drugs
- Neoplasm 671 drugs
- Glandular and epithelial neoplasm 12 drugs
- Head and neck neoplasms 184 drugs
- Otorhinolaryngologic disease 4 drugs
- Respiratory disease 57 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D009062 “Mouth Neoplasms”.